• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 438907 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413803130 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413803130 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Antares Pharma Ranks the Highest in Terms of Revenue Per Employee in the Health Care Supplies Industry (AIS, VIVO, CERS)

Published on Fri, 02/08/2013 - 11:18
By Peter Chu

Below are the three companies in the Health Care Supplies industry with the highest Revenue Per Employee (RPE). Analysts use RPE as a measure to compare the productivity of companies in the same industry.

Antares Pharma (AMEX:AIS) is highest with an RPE of $1.1 million. Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The Company distributes its needle-free injector systems in various countries. Antares also conducts research and development with transdermal gel products and has several products in clinical evaluation with partners.

Potential upside of 61.6% exists for Antares Pharma, based on a current level of $3.30 and analysts' average consensus price target of $5.33. The stock should find initial support at its 50-day moving average (MA) of $3.04 and further support at its 200-day MA of $2.60.

Meridian Bioscience (NASDAQ:VIVO) is next with an RPE of $629,000.

Finishing up the top three is Cerus (NASDAQ:CERS), with an RPE of $464,000.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

McCormick & Co Earnings Hindsight: Down ...

When McCormick & Co (NYSE:MKC) reported earnings two weeks ago on October 2nd, 2014, an ...

Shares of Strayer Education Have Risen A...

Shares of Strayer Education (NASDAQ:STRA) traded today at $64.79, breaking its 52-week ...

Shares of Sonic Rise Above Previous 52-W...

Shares of Sonic (NASDAQ:SONC) traded today at $23.96, breaking its 52-week high. So fa ...

Shares of Sciclone Pharmaceuticals Rise ...

Shares of Sciclone Pharmaceuticals (NASDAQ:SCLN) traded at a new 52-week high today of ...

Shares of Regeneron Pharmaceuticals Rise...

Regeneron Pharmaceuticals (NASDAQ:REGN) traded today at a new 52-week high of $376.88. ...

Shares of RadNet Have Risen Above Previo...

Shares of RadNet (NASDAQ:RDNT) traded at a new 52-week high today of $8.72. Approximat ...

Recent 52-Week High Exceeded in Shares o...

The Pantry (NASDAQ:PTRY) traded today at a new 52-week high of $24.55. So far today ap ...

Nestle Looks to Continue to Trade Below ...

Shares of Nestle (NASDAQ:NSRGY) traded today at $65.79, breaking its 52-week low. This ...